Delving into the Latest Updates on Para-Toluenesulfonamide with Synapse

Pancreatic alpha amylase (P-AMY) is used as a biomarker of acute pancreatitis (AP) in human medicine. To our knowledge, there are no studies evaluating the usefulness of P-AMY in dogs with AP. In this study, we evaluated the diagnostic value of P-AMY, currently not verified in veterinary medicine. The AP group (n = 40) consisted of dogs with AP diagnosed using clinical signs and laboratory examinations, including abnormal canine pancreatic lipase (cPL) concentration, and compatible abdominal ultrasound examination at first presentation. Evaluation of the canine AP severity (CAPS) score was performed. The control group (n = 38) was composed of normal dogs without any abnormalities in clinical findings, blood exams or diagnostic imaging. The correlation of P-AMY with cPL was confirmed by Pearson's correlation analysis (r = 0.564, p < .001). The sensitivity and specificity for the most appropriate cut-off values of P-AMY were recorded similar to the values of DGGR. The dogs with AP and CAPS ≥11 had significantly higher serum P-AMY (p = .016) contrary to DGGR lipase and cPL. Furthermore, there was a significant difference in the median P-AMY dependent on the presence of systemic inflammatory response syndrome (p = .001). P-AMY showed similar level of diagnostic accuracy along with sensitivity and specificity compared to DGGR lipase. In addition, P-AMY showed a significant association with CAPS score, contrary to cPL and DGGR lipase. Along with other biomarkers associated with AP, P-AMY has the potential of usefulness as a supportive diagnostic and prognostic biomarker of AP in dogs.

01 Jul 2024·Journal of Ethnopharmacology

Bioinformatics and LC-QTOF-MS based discovery of pharmacodynamic and Q-markers of Pitongshu against functional dyspepsia

Article

Author: Wang, Kun-Gen ; Wu, Han-Song ; Shen, Shu-Hua ; Lv, Gui-Yuan ; Dong, Ying-Jie ; Jiang, Xiao-Feng ; Bian, Xue-Ren ; He, Xinglishang ; Chen, Su-Hong ; Zhi, Yi-Hui ; Li, Bo ; Zhou, Cong

ETHNOPHARMACOLOGICAL RELEVANCEPitongshu (PTS) is a clinically effective empirical formula for the treatment of FD. The efficacy and safety of PTS have been demonstrated in randomized, controlled, double-blind trials, but there is a lack of understanding of the systematic evaluation of the efficacy of PTS and its material basis.OBJECTIVETo investigate the efficacy of PTS in Functional dyspepsia (FD) mice and possible Q-markers.METHODIn this study, we used "irregular feeding + chronic unpredictable chronic stimulation" to establish a mice model of FD with hepatogastric disharmony. The efficacy of PTS was assessed from hair condition, behavioral, pain, gastrointestinal function, and serum 5-HT, GAS, MTL levels in mice by instillation of different doses of PTS. In addition, the composition of drugs in blood was analyzed by LC-QTOF-MS and potential Q-markers were selected by combining network pharmacology, molecular docking and actual content.RESULTOur study showed that different doses of PTS increased pain threshold and writhing latency, decreased the number of writhings, increased gastric emptying rate and small intestinal propulsion rate, decreased total acidity of gastric contents and gastric acid secretion, and increased serum levels of 5-HT, GAS, and MTL in mice to different degrees. Enrichment analysis showed that PTS may be anti-FD through multiple pathways such as Serotonergic synapse, thyroid hormone signaling pathway, cholinergic synapse, and dopaminergic synapse. In addition, potential active ingredient substances were explored by LC-QTOF-MS combined with bioinformatics. Combined with the actual contentselected six constituents, hesperidin, neohesperidin, naringin, paeoniflorin, magnolol and honokiol, possible as Q-markers.CONCLUSIONPTS may exert its anti-FD effects through multi-component, multi-target and multi-pathway". Constituents, hesperidin, neohesperidin, naringin, paeoniflorin, magnolol and honokiol may be the Q-markers of its anti-FD effects.

01 May 2024·The American Journal of Cardiology

Distal Versus Proximal Radial Arterial Access for Percutaneous Coronary Angiography and Intervention: Updated Meta-Analysis of Randomized Controlled Trials

Article

Author: Saleem, Sameer ; Mufarrih, Syed Hamza ; Kazimuddin, Mohammed ; Haider, Sajjad ; Singh, Aniruddha ; Khan, Mohammad Saud ; Tripathi, Avnish ; Mufarrih, Syeda Aleena ; Waheed, Mohammad Abdul ; Akbar, Muhammad Shoaib ; Qureshi, Nada Qaisar

Radial artery occlusion (RAO) is a major impediment to reintervention in patients who underwent proximal transradial access (p-TRA) for coronary catheterization. Distal transradial access (d-TRA) at the level of snuffbox distal to the radial artery bifurcation is a novel alternative to p-TRA. We conducted an updated meta-analysis of all available randomized controlled trials (RCTs) to compare the incidence of RAO between p-TRA and d-TRA, along with access site-related complications. PubMed, Web of Science, and Google Scholar were searched for RCTs published since 2017 to October 2023 comparing d-TRA and p-TRA for coronary angiography and/or intervention. Risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals were calculated using the random-effects model for procedural and clinical outcomes for the 2 approaches. A total of 18 RCTs with 8,205 patients (d-TRA n = 4,096, p-TRA n = 4,109) were included. The risk of RAO (RR 0.31, 0.21 to 0.46, p ≤0.001) and time to hemostasis (minutes) (MD -51.18, -70.62 to -31.73, p <0.001) was significantly lower in the d-TRA group. Crossover rates (RR 2.39, 1.71 to 3.32, p <0.001), access time (minutes) (MD 0.93, 0.50 to 1.37, p <0.001), procedural pain (MD 0.46, 0.13 to 0.79, p = 0.006), and multiple puncture attempts (RR 2.13, 1.10 to 4.11, p = 0.03) were significantly higher in the d-TRA group. The use of d-TRA for coronary angiography and/or intervention is associated with a lower risk of RAO at the forearm and may preserve p-TRA site for reintervention in selective patients by reducing the incidence of RAO.

100 Deals associated with Para-Toluenesulfonamide

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	CN	Tianjin Hongri Jiandakang Medical Technology Co Ltd	15 Nov 2022

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adenoid Cystic Carcinoma	Phase 2	CN	Tianjin Chase Sun Pharmaceutical Co., Ltd.	15 May 2014
Airway Obstruction	Phase 2	CN	Beijing Jiandakang New Drug Development Co Ltd	30 Oct 2009
Non-Small Cell Lung Cancer	Phase 2	CN	Pts International Inc	01 Aug 2009
occlusions	Phase 2	CN	Pts International Inc	01 Aug 2009
Liver Cancer	Phase 2	CN	-	02 Dec 2005
Lung Cancer	Phase 2	CN	-	22 Apr 2005
Hepatocellular Carcinoma	Phase 1	CN	Tianjin Hongri Jiandakang Medical Technology Co Ltd	15 May 2014
Advanced Malignant Solid Neoplasm	Phase 1	CN	-	12 Aug 2005
Adenoid Cystic Carcinoma	Preclinical	CN	Tianjin Hongri Jiandakang Medical Technology Co Ltd	15 May 2014
Hepatocellular Carcinoma	Preclinical	CN	Tianjin Chase Sun Pharmaceutical Co., Ltd.	15 May 2014